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Abstract
Thymosin beta 4 (Tβ4) and thymosin beta
10 (Tβ10) are two members of the beta-thy-
mosin family involved in many cellular
processes such as cellular motility, angiogene-
sis, inflammation, cell survival and wound
healing. Recently, a role for beta-thymosins
has been proposed in the process of carcino-
genesis as both peptides were detected in sev-
eral types of cancer. The aim of the present
study was to investigate the expression pattern
of Tβ4 and Tβ10 in hepatocellular carcinoma
(HCC). To this end, the expression pattern of
both peptides was analyzed in liver samples
obtained from 23 subjects diagnosed with
HCC. Routinely formalin-fixed and paraffin-
embedded liver samples were immunostained
by indirect immunohistochemistry with poly-
clonal antibodies to Tβ4 and Tβ10.
Immunoreactivity for Tβ4 and Tβ10 was
detected in the liver parenchyma of the sur-
rounding tumor area. Both peptides showed an
increase in granular reactivity from the peri-
portal to the periterminal hepatocytes.
Regarding HCC, Tβ4 reactivity was detected in
7/23 cases (30%) and Tβ10 reactivity in 22/23
(96%) cases analyzed, adding HCC to human
cancers that express these beta-thymosins.
Intriguing finding was seen looking at the
reactivity of both peptides in tumor cells infil-
trating the surrounding liver. Where Tβ10
showed a strong homogeneous expression,
was Tβ4 completely absent in cells undergoing
stromal invasion.
The current study shows expression of both
beta-thymosins in HCC with marked differ-
ences in their degree of expression and fre-
quency of immunoreactivity. The higher inci-
dence of Tβ10 expression and its higher reac-
tivity in tumor cells involved in stromal inva-
sion indicate a possible major role for Tβ10 in
HCC progression.
Introduction
Thymosins are a group of naturally occur-
ring, small bioactive peptides. After their isola-
tion from the calf thymus in 1966,1 they have
been divided into three distinct classes based
on their isoelectric point: alpha thymosins
(pH<5.0), beta thymosins (pH between 5.0 and
7.0) and gamma thymosins (pH>7.0).2 In
humans, three beta thymosins have been iden-
tified to date: thymosin β4, β10 and β15.3
Thymosin beta 4 (Tβ4) is considered to be the
most abundant subtype (70-80%) of the beta
thymosin family in mammalian tissues.4 This
43 amino acid peptide is seen as the main
actin monomer sequestering molecule.
Alongside its pivotal role in cellular motility,
Tβ4 has a broad range of other biological activ-
ities, mainly focused on angiogenesis, inflam-
mation, cell survival and wound healing.5
Thymosin beta 10 (Tβ10) is another member
of the beta thymosin family. This 43 amino
acid peptide is generally reported to be much
less abundant (5-10%) and is, together with
Tβ4, the main actin sequestering molecule.6
Although both peptides are highly homologues
(up to 77%), they exert different effects on
processes such as angiogenesis and apopto-
sis:7 as Tβ4 promotes angiogenesis, Tβ10 has
been shown to inhibit angiogenesis by inter-
fering with the RAS oncoprotein;8 whereas Tβ4
plays an important role as anti-apoptotic pep-
tide, overexpression of Tβ10 has been associ-
ated with accelerated apoptosis.9 Over the past
few years, several studies have been conduct-
ed on the expression pattern of beta-thymosins
in different organs in adulthood10-12 and their
role in embryogenesis and in carcinogenesis.
It has been shown that Tβ4 is highly expressed
during embryonic development, followed by a
downregulation during adulthood and again an
upregulation in several tumors. This suggests
that tumor cells might utilize fetal programs,
including Tβ4 synthesis.13 A 2012 study by
Nemolato et al. revealed a strong Tβ4 expres-
sion in epithelial cells undergoing epithelial
mesenchymal transition (EMT) in colorectal
cancer. This high expression of Tβ4 was asso-
ciated with a downregulation of E-cadherin,
which might implicate a role for Tβ4 in car-
cinogenesis and metastasis.14 Besides, also
Tβ10 expression has been detected in several
tumors. Intensity of Tβ10 expression levels
correlated significantly with the stage of both
breast15 and lung cancer.16 Blocking of this pep-
tide in thyroid cancer resulted in a significant
decrease in tumor growth.17 These results
implicate a possible role for both Tβ4 and Tβ10
as molecular markers and therapeutic targets
in several tumors. 
On the basis of these data, suggesting that
beta-thymosins might play a pivotal role in car-
cinogenesis, this study was focused on the
analysis of the expression pattern of Tβ4 and
Tβ10 in hepatocellular carcinoma (HCC).
Materials and Methods
The study included archival paraffin-embed-
ded liver samples obtained from 23 consecu-
tive subjects diagnosed with HCC in the
Department of Pathology of the University
Hospital of Cagliari. In order to avoid sampling
variability in Tβ4 and Tβ10 expression, only
surgically-resected tumors were included. The
age of the subjects (15 males and 8 females)
ranged from 43 up to 76 years. The main clini-
cal data of the HCC cases are reported in Table
1. As a control group, we used 9 liver biopsies
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from adult subjects with very mild pathological
changes, that were immunostained for Tβ4
and Tβ10.
All liver samples were routinely formalin-
fixed and paraffin-embedded; immunostaining
of 4 µm sections was performed by indirect
immunohistochemistry. For each tumor, two
samples were immunostained with either Tβ4
or Tβ10 antibody. In case 1, 2, 3, 16 and 20 mul-
tiple samples were analyzed, in order to verify
if both peptides were homogeneously
expressed throughout the tumor mass. All
slides were deparaffinized, rehydrated and
endogenous peroxidase activity was blocked by
0,3% hydrogen peroxide (H2O2) in methanol.
Subsequently, slides were subjected to antigen
retrieval by heat-induced epitope retrieval
(HIER) using the target retrieval solution
(Dako TRS pH 6.1; Dako, Glostrup, Denmark)
for 30 min. This was followed by incubation
with a polyclonal antibody to Tβ4 (Bachem-
Peninsula Lab, San Carlos, CA, USA, catalog
number T-4848, diluted 1:600) or Tβ10
(Bachem-Peninsula Lab, catalog number
ab14338, diluted 1:400). Slides were extensive-
ly washed and subjected to a biotinylated sec-
ondary antibody (Envision kit). After second-
ary antibody incubation, streptavidin peroxi-
dase (HRP) and AEC chromogen were added.
The AEC chromogen formed a red end-product
at the site of target antigen. Slides were coun-
terstained with hematoxylin and mounted. As
a positive control, sections of adult human
liver were utilized.
A semi-quantitative grading system was
used for the evaluation of Tβ4 and Tβ10
immunoreactivity, based on the percentage of
immunoreactive tumor cells: 0 (<5%); 1 (5-
10%); 2 (10-50%); 3 (>50%).
Results
Immunoreactivity for Tβ4 and Tβ10 was
observed in three patterns: a homogeneous
staining diffusely distributed over the entire
cytoplasm of the hepatocytes; a punctuated and
granular staining localized in the cytoplasm; a
granular staining localized in perinuclear
regions, which possibly represents a localiza-
tion at the trans-Golgi network. In all cases, no
nuclear expression was detected.Control group
Both Tβ4 and Tβ10 expression was detected
in all 9 liver biopsies of normal livers without
cancer. Tβ4 appeared as large granules in the
cytoplasm, different in shape and size. The
staining was not homogeneously diffuse to the
entire parenchyma, but it was mainly stored in
periterminal hepatocytes (zone 3 of the aci-
nus) (Figure 1A), while a minor degree of
reactivity was detected in periportal hepatocy-
tes (zone 1). Immunostaining for Tβ10 was
characterized by a diffuse cytoplasmic reacti-
vity in the vast majority of hepatocytes of all
acinar zone. Morover, a mild granular immu-
noreactivity was detected in zone 3 hepatocy-
tes (Figure 1B).
Normal liver parenchyma sur-rounding hepatocellular carcinoma
Both Tβ4 and Tβ10 expression was detected
in the liver parenchyma surrounding HCC in
all cases analyzed. Tβ4 appeared as large gran-
ules in the cytoplasm, different in shape and
Original Paper
Table 1. Clinical data of 23 patients diagnosed with hepatocellular carcinoma.
Case Nº Age Gender Follow up Follow up 
until death (months) until last 
hospitalization (months)
1* 61 M 49.9
2* 57 F 23.2
3* 54 F 7.1
4 66 M 52.1
5 69 M 56.3
6 76 F 14.9
7 66 M 8.3
8 58 M 45.3
9 44 M 0.2
10 69 M 9.5
11 70 F 41.1
12 76 F 0.2
13 54 M 56.0
14 64 M 40.3
15 74 M 65.0
16* 70 M 2.0
17 70 M 10.7
18 48 M 73.4
19 43 M 7.3
20* 69 F 47.2
21 63 F 3.5
22 48 M 0.3
23 72 F 33.2
*Multiple samples analyzed. 
Figure 1. Immunoreactivity of Tβ4 and Tβ10 (stained in red) in the control group. A)
Tβ4 granular staining localized in the periterminal hepatocytes. B) Tβ10 homogeneous
and granular staining in the cytoplasm of periterminal hepatocytes. 
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size (Figure 2B). Tβ10 was seen as cytoplas-
mic granules or as a homogeneous staining
over the entire cytoplasm (Figure 2D). A sub-
stantial difference was observed in the zona-
tion pattern of Tβ4 and Tβ10. The degree of
granular reactivity for Tβ4 (Figure 2A) and
Tβ10 (Figure 2C) increased from the peripor-
tal hepatocytes (zone 1 of acinus) towards the
periterminal hepatocytes (zone 3 of acinus).
Especially Tβ4 showed a high increase in
immunoreactivity towards the terminal vein.
No zonation pattern was detected for the
homogeneous expression of Tβ10, that was
diffusely expressed over the entire liver
parenchyma surrounding the tumor mass. Hepatocellular carcinoma
Immunoreactivity for Tβ4 was detected in 7
out of 23 (30%) HCC samples. Grade 1 in 6
cases and grade 3 in 1 case (Figure 3). Tβ10
reactivity was observed in 22 out of 23 (96%)
HCC samples. Grade 1 in 9 cases, grade 2 in 7
cases and grade 3 in 6 cases (Figure 3). For
both beta-thymosins, no relationship was
found between the degree of immunoreactivity
and age or gender of the subjects.
Immunostaining for both peptides was pre-
dominantly homogeneous and diffusely dis-
tributed over the entire cytoplasm. In the
tumor mass, no zonation pattern for these
beta-thymosins was observed. Remarkable dif-
ferences were seen regarding the degree of
immunoreactivity between the two peptides. In
21 out of 23 cases (91%) Tβ10 reactivity was
higher when compared to Tβ4 immunostain-
ing (Figure 3), in one case Tβ10 reactivity was
similar to Tβ4 and in one case Tβ4 exceeded
Tβ10 reactivity (Figure 3). 
An intriguing finding was represented by
the peculiar immunohistochemical pattern
observed in case Nº18 were both peptides were
highly expressed. In this case, four different
clones with a different reactivity pattern and
reactivity intensity were observed: a punctuat-
ed and granular staining localized in the perin-
uclear zone (Figure 4A); a homogenous stain-
ing reactivity distributed over the entire cyto-
plasm (Figure 4B); a homogeneous staining in
combination with granular reactivity (Figure
4C); absence of reactivity for both peptides in
one clone (Figure 4D). In 9 out of 23 cases
(39%) immunostaining for Tβ4 and Tβ10 was
markedly uneven. In these HCCs, different
tumor clones were detected showing a marked
variability regarding the intensity of expres-
sion of both peptides (Figure 5). No relation-
ship was seen between the degree of Tβ4 and
Tβ10 immunostaining and tumor grade in
these cases. Analysis of the 5 HCC cases in
which multiple samples were obtained,
revealed that both Tβ4 and Tβ10 were uneven-
ly expressed over all the samples. In particular
in case Nº16 were the degree of reactivity for
Original Paper
Figure 2. Expression of Tβ4 and Tβ10 (stained in red) in the same field of normal sur-
rounding liver parenchyma. A) Tβ4 shows an increase in the degree of immunostaining
from the periportal to the periterminal acinar zones; PT, portal tract. B) A strong gran-
ular expression pattern for Tβ4 is observed in the periterminal hepatocytes; TV, terminal
vein. C) Two expression patterns of Tβ10 are observed: granular reactivity in peritermi-
nal hepatocytes and homogeneous reactivity without a zonation pattern; PT, portal tract.
D) Tβ10 is both granular and homogeneously expressed in the hepatocytes surrounding
the terminal vein; TV, terminal vein.
Figure 3. Overview of the degree of reactivity for Tβ4 and Tβ10 in all 23 liver samples
diagnosed with hepatocellular carcinoma. Tβ4 was present in 7 of the 23 cases (30%),
whereas Tβ10 was detected in 22 of the 23 cases (96%).
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Tβ4 and Tβ10 ranged from grade 0 up to grade
2, and in case Nº20 from grade 0 up to grade 3.
On this basis, in order to avoid mistakes due to
sampling variability, all needle biopsies and
tissue microarrays were excluded from the
present study. When the degree of immunore-
activity for Tβ4 and Tβ10 was compared with
tumor grade according to Edmondson,18 reac-
tivity for Tβ10 was detected in the entire spec-
trum of tumor grades (I-IV). On the contrary,
Tβ4 reactivity was predominantly seen in
grade I and grade II tumors, being absent in
vast majority of the poorly differentiated HCCs.
The only grade III HCC with Tβ4 immunoreac-
tivity was a relatively small tumor (1.5 cm in
diameter) compared to all other grade III
tumors (Figure 6). In six cases, in which a
complete fibrous capsule was absent, HCC was
characterized by infiltrative margins with
small tumor nests infiltrating the surrounding
liver. When immunohistochemistry for Tβ4
and Tβ10 was applied to these cases, infiltrat-
ing tumor cells showed a strong immunoreac-
tivity for Tβ10 (Figure 7C and 7D), in the
absence of any significance reactivity for Tβ4
(Figure 7A and 7B).
Discussion
Several recent studies have identified that
beta-thymosins, including Tβ4 and Tβ10, are
highly expressed in some cancer cells.6 In par-
ticular, Tβ4 has been described to be upregu-
lated in colon cancer.19,20 When Tβ4 expression
was analyzed by immunohistochemistry in the
whole colon cancer mass, the peptide was
mainly localized in tumor cells undergoing
epithelial mesenchymal transition (EMT) at
the deep infiltrative margins14 suggesting a
major role for Tβ4 in enhancing the migration
ability and the metastatic behavior of tumor
cells in colon cancer.21 Taken all together, these
data indicate Tβ4 expression as a poor prog-
nostic indicator, being associated with poor
overall survival in patients affected by colon
cancer. On the basis of these data, it has been
hypothesized that Tβ4 might represent a feasi-
ble therapeutic target for human colorectal
cancer.22 Tβ10, the other beta-thymosin highly
expressed in human tissues, has been report-
ed to be upregulated in multiple human
tumors, including pancreatic cancer,23
melanoma24 and in multiple tumor cell lines
including colon cancer, thyroid cancer, breast
cancer, ovarian cancer, uterine and esophageal
cancer cells.25 In human thyroid carcinoma
cells, Tβ10 expression reached the highest lev-
els in anaplastic carcinoma, whereas the pep-
tide was absent in normal thyroid tissue and in
thyroid adenoma, indicating immunoreactivity
for Tβ10 as a possible tool in the diagnosis of
Original Paper
Figure 5. Two different tumor clones of the same hepatocellular carcinoma stained with
Tβ4. A) One clone with red granular Tβ4 reactivity. B) The other clone with no Tβ4
reactivity.
Figure 4. Four different tumor clones in the same hepatocellular carcinoma stained with
Tβ10 (stained in red). A) A granular staining localized in the perinuclear regions. B) A
homogeneous staining diffusely distributed over the entire cytoplasm. C) A homoge-
neous staining in combination with a granular staining in the perinuclear area. D) No
reactivity. 
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thyroid neoplasias.26
In the present study, we first report that both
Tβ4 and Tβ10 are expressed in human HCC
cells, adding HCC to the series of human can-
cers that express these beta-thymosins.
Immunostaining for both thymosins was
detected in the surrounding liver in all cases
analyzed, as well as in the 9 control liver biop-
sies in which no tumor was detected. This
finding confirms previous studies from our
group on the high expression of Tβ4 in the
adult normal human liver27 and add Tβ10 to the
list of beta-thymosins highly expressed in the
hepatocytes in adulthood. Interestingly, in this
study some differences were found between
Tβ4 and Tβ10 regarding the expression pat-
tern and the acinar zones involved in their dis-
tribution. Whereas Tβ4 immunostaining was
characterized by a granular reactivity,
immunoreactivity for Tβ10 showed two stain-
ing patterns: a granular reactivity and a homo-
geneous diffuse cytoplasmic staining.
Moreover, whereas a clear zonation was
observed for Tβ4 with zone 3 hepatocytes
being mainly involved in its expression, reac-
tivity for Tβ10 was less compartmentalized: in
particular, the homogeneous immunoreactivi-
ty for Tβ10 was detected in periportal hepato-
cytes (zone 1 of acinus) as well as in periter-
minal hepatocytes (zone 3 of acinus) (Figure
2A and 2C). Immunoreactivity for both beta-
thymosins was high in periterminal hepato-
cytes (zone 3 of acinus) and highly expressed
in the same hepatocytes (Figure 2B and 2D),
suggesting a major role of liver cells in beta-
thymosin production and, possibly, secretion
in blood. The expression pattern, the degree of
expression and the frequency of immunoreac-
tivity for these two beta-thymosins in HCCs
showed marked differences, that deserve some
considerations. Tβ10 was expressed in the
vast majority of tumors, being detected in 22
out of 23 cases. Moreover, the degree of
immunoreactivity was very high in 6 cases
(grade 3) and high in 7 cases (grade 2). On the
contrary, reactivity for Tβ4 was detected only
in 7 out of 23 cases, being characterized by low
levels (grade 1) of immunostaining  in 6 out of
7 positive cases. In one case, both thymosins
were highly expressed. The expression pattern
of Tβ4 and Tβ10 was characterized by a patchy
distribution, with some positive tumor clones
adjacent to completely negative tumor areas.
The variability of immunostaining for both
peptides was more evident in the five cases in
which multiple tumor samples were studied.
Sampling variability was particularly evident
in case Nº20, where in one tumor sample
immunoreactivity for both beta-thymosins was
completely absent, whereas in another sample
tumor cells were characterized by very high
levels (grade 3) of reactivity for Tβ4 and Tβ10.
These findings confirm the previously reported
Original Paper
Figure 6. Degree of immunoreactivity of Tβ4 and Tβ10 compared with the tumor grade
according to Edmondson. Tβ4 is mainly present in well differentiated tumors; Tβ10 is
present in the entire spectrum of tumor grades.
Figure 7. Immunoreactivity of Tβ4 and Tβ10 in small tumor nests infiltrating the sur-
rounding liver. A, B) Tβ4 immunostaining is absent in the infiltrating cells. C, D) Tβ10
shows a clear, red, homogeneous reactivity in the infiltrating cells.
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intratumoral sampling variability in HCC for
Glypican 3 and for other immunohistochemical
markers,28 confirming the heterogeneity of
tumor clones and tumor cells within each HCC.
Moreover, our data clearly indicate that cau-
tion should be taken in the interpretation of
immunostaining for Tβ4 and Tβ10 when
determined in a small needle biopsy. Due to
the variability of immunoreactivity for these
beta-thymosins in different tumor clones, the
immunostaining  for Tβ4 and Tβ10 should not
be considered as absolutely representative and
reliable of their expression in the whole tumor
mass. An interesting finding, regarding the
function of beta-thymosin expression in HCC
is represented by the high reactivity of tumor
cells infiltrating the surrounding liver for
Tβ10. This reactivity contrasts with the
absence of immunostaining for Tβ4. In a pre-
vious study from our group, a major role has
been hypothesized for Tβ4 in colon cancer,
Tβ4 reactivity being strictly associated with
the process of EMT at the deep infiltrative mar-
gins of the tumor mass.14 This study confirms
the association of beta-thymosins with the
infiltrating ability of tumor cells, but shows
that each single tumor may utilize different
beta-thymosins. Whereas colon cancer cells
use, to this end, Tβ4, here we show that HCC
cells utilize Tβ10. In conclusion, our prelimi-
nary data suggest a role for Tβ4 and Tβ10 in
liver carcinogenesis. Further studies are need-
ed in order to shed light on the intimate signif-
icance of the expression of these thymosins
not only during liver carcinogenesis, but main-
ly in HCC progression. Moreover, studies com-
paring serum levels of Tβ4 and Tβ10 with
immunoreactivity for both peptides in tumor
cells are needed. The higher incidence of Tβ10
expression detected in the vast majority of
HCCs and its higher reactivity in small tumor
nests infiltrating the surrounding liver indi-
cate a major role for Tβ10 in HCC progression
and in its metastatic ability. These data con-
firm previous hypotheses indicating Tβ10 as a
new progression marker for multiple human
tumors24 and indicate Tβ10 as a promising
marker and a possible novel therapeutic target
for liver cancer.  
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